Using Pentoxifylline to help treat ulcerative colitis
Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.
This study is testing if pentoxifylline can help adults with ulcerative colitis feel better by reducing inflammation and improving their overall health.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 44 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Al Mansurah) |
| Trial ID | NCT05575505 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of pentoxifylline, a phosphodiesterase inhibitor, as an adjunctive therapy for patients suffering from ulcerative colitis (UC). The study aims to evaluate the effectiveness of this medication in reducing inflammation and improving outcomes for individuals with this chronic condition. Participants will be monitored for their response to the treatment, and the trial will include both male and female adults aged 18 and older. The goal is to find new therapeutic options for managing UC, which is associated with a high risk of colon cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with ulcerative colitis who meet the inclusion criteria.
Not a fit: Patients with severe ulcerative colitis, colorectal cancer, or those currently on immunosuppressive therapies may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with ulcerative colitis, potentially improving their quality of life and reducing disease progression.
How similar studies have performed: While the specific use of pentoxifylline for ulcerative colitis is less common, similar studies exploring adjunctive therapies for inflammatory bowel diseases have shown promise.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Both males and females will be included * Negative pregnancy test and effective contraception. Exclusion Criteria: * Breastfeeding * Significant liver and kidney function abnormalities * Colorectal cancer patients * Patients with severe UC * Patients taking rectal or systemic steroids * Patients taking immunosuppressives or biological therapies * Addiction to alcohol and / or drugs
Where this trial is running
Al Mansurah
- Faculty of Medicine, Mansoura University — Al Mansurah, Egypt (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.